Table 5.
Interleukin-28B polymorphism in sofosbuvir and ABT-450 era
| Group | Status before treatment | IL-28B CC (n) | IL-28B CT (n) | IL-28B TT (n) | SVR rate |
| Sofosbuvir | |||||
| 1 | Untreated | 5 | 4 | 1 | 100% |
| 2 | Untreated | 4 | 4 | 1 | 100% |
| 3 | Untreated | 4 | 4 | 2 | 100% |
| 4 | Untreated | 4 | 5 | 2 | 100% |
| 5 | Untreated | 2 | 6 | 2 | 60% |
| 6 | Untreated | 3 | 6 | 1 | 100% |
| 7 | No response to prior therapy | 2 | 5 | 3 | 10% |
| 8 | Untreated | 11 | 12 | 2 | 84% |
| ABT-450 | |||||
| 1 | Untreated | 10/9 | 7/7 | 2/2 | 95% |
| 2 | Untreated | 5/4 | 7/7 | 2/2 | 93% |
| 3 | No or partial response to prior therapy | 0/0 | 12/6 | 5/2 | 47% |
IL-28B: Interleukin-28B; SVR: Sustained virologic response.